1. COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS. (12th June 2019) Authors: Tarantelli, C.; Lange, M.; Gaudio, E.; Cascione, L.; Spriano, F.; Kwee, I.; Arribas, A.; Rinaldi, A.; Jourdan, T.; Berthold, M.; Margheriti, F.; Gritti, G.; Rossi, D.; Stathis, A.; Liu, N.; Zucca, E.; Politz, O.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THE FIRST‐IN‐CLASS ETS INHIBITOR TK‐216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA. (12th June 2019) Authors: Spriano, F.; Chung, E.; Napoli, S.; Tarantelli, C.; Gaudio, E.; Cascione, L.; Cavalli, A.; Rinaldi, A.; Kwee, I.; Ye, H.; Rossi, D.; Zucca, E.; Stathis, A.; Jessen, K.; Lannutti, B.; Toretsky, J.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 322 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. COMBINATORIAL SCREENING OF THE PI3K INHIBITOR COPANLISIB IN T CELL LYMPHOMAS. (June 2017) Authors: Gaudio, E.; Kwee, I.; Spriano, F.; Tarantelli, C.; Rinaldi, A.; Jourdan, T.; Berthold, M.; Arribas, A.; Stathis, A.; Rossi, D.; Liu, N.; Lange, M.; Politz, O.; Zucca, E.; Bertoni, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DEVELOPMENT OF NOVEL PRECLINICAL MODELS OF SECONDARY RESISTANCE TO THE PI3KΔ INHIBITOR IDELALISIB IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL). (June 2017) Authors: Arribas, A.J.; Gaudio, E.; Rinaldi, A.; Cascione, L.; Tarantelli, C.; Kwee, I.; Stathis, A.; Zucca, E.; Rossi, D.; Bertoni, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. (8th March 2016) Authors: Gaudio, E.; Tarantelli, C.; Kwee, I.; Barassi, C.; Bernasconi, E.; Rinaldi, A.; Ponzoni, M.; Cascione, L.; Targa, A.; Stathis, A.; Goodstal, S.; Zucca, E.; Bertoni, F. Journal: Annals of oncology Issue: Volume 27:Number 6(2016:Jun.) Page Start: 1123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The BET bromodomain inhibitor (BET-i) BAY 1238097: Mechanism of action and pre-clinical activity in diffuse large B-cell lymphoma (DLBCL). (December 2016) Authors: Bernasconi, E.; Gaudio, E.; Lejeune, P.; Tarantelli, C.; Rinaldi, A.; Kwee, I.; Mensah, A.A.; Chung, E.Y.L.; Stathis, A.; Ocker, M.; Zucca, E.; Haendler, B.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. ETS1 POSITIVELY REGULATES FAIM3 IN ACTIVATED B CELL‐LIKE (ABC) DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). (June 2017) Authors: Priebe, V.; Chung, E.Y.; Cascione, L.; Kwee, I.; Arribas, A.; Sartori, G.; Napoli, S.; Rinaldi, A.; Mensah, A.A.; Ponzoni, M.; Zucca, E.; Rossi, D.; Lenz, G.; Thome, M.; Bertoni, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL). (December 2016) Authors: Arribas, A.; Rinaldi, A.; Spriano, F.; Tarantelli, C.; Gaudio, E.; Bernasconi, E.; Hillmann, P.; Kwee, I.; Stathis, A.; Fabbro, D.; Stüssi, G.; Zucca, E.; Rossi, D.; Cmiljanovic, V.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The novel mTORC1/2 inhibitor PQR620 has in vitro and in vivo activity in lymphomas. (December 2016) Authors: Tarantelli, C.; Gaudio, E.; Hillmann, P.; Spriano, F.; Rinaldi, A.; Kwee, I.; Cascione, L.; Fabbro, D.; Stathis, A.; Zucca, E.; Cmiljanovic, V.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗